Kornimate/medical-research-clean huggingface dataset:
comfortable and stabilizing chin & forehead rest attachment for slit lamp configurations

Conditions: Age-Related Macular Degeneration; Diabetic Retinopathy; Central Serous Chorioretinopathy; Glaucoma; Glaucoma, Suspect; Eye Diseases

Summary: in this study, participants will be imaged using two optical coherence tomography (oct) devices: device n, a standard conventional oct device with an invention (comfortable chin and forehead rest that can be adjusted to fit each individual's size) attached to the device; and device c, the standard conventional oct device with no invention attached. the investigators will assess whether the chin and forehead rest attachment (invention) provides a more comfortable experience for patients.


Eligibility criteria:
inclusion criteria: * healthy volunteers; or, * amd, diabetic retinopathy, central serous chorioretinopathy, and/or glaucoma or glaucoma suspects or any other suspected eye disease group-specific inclusion criteria: -- there are no group-specific inclusion criteria for patients with amd, diabetic retinopathy, and central serous chorioretinopathy. healthy volunteers * a normal clinical ophthalmic examination. * reliable vf, reproducible glaucoma hemifield tests labeled within normal limits on at least one test. * good quality (adequate signal strength ≥ 6/10, without segmentation algorithm failure and motion artifacts \> 1 vessel diameter) rnfl and ganglion cell inner plexiform layer (gcipl) oct, within normal limits. primary open angle glaucoma (poag) * clinical characteristics of glaucoma: optic nerve head (onh) abnormalities: global rim thinning, rim notch, or disc hemorrhage; retinal nerve fiber layer (rnfl) defect. * typical glaucomatous field loss in reliable vf, reproducible glaucoma hemifield tests labeled outside normal limits on at least two consecutive tests. * good quality (adequate signal strength ≥ 6/10, without segmentation algorithm failure and motion artifacts \> 1 vessel diameter) rnfl and gcipl oct, labeled outside normal limits with typical glaucomatous rnfl and gcil thinning. normal tension glaucoma (ntg) * identical to poag criteria with iop recorded at ≤ 21 mmhg at any time point. exclusion criteria: an individual who meets any of the following criteria will be excluded from participation in this study: - any medical treatment (e.g., chronic corticosteroid, hydroxychloroquine, chloroquine, thioridazine, canthaxanthine) or conditions that affect vf (e.g., stroke) and retinal thickness other than glaucoma.
the effectiveness of eptinezumab during a migraine attack (the be-free study): a tachis sub-study

Conditions: Migraine

Summary: a perspective and multicentric study to evaluate the efficacy of eptinezumab administered during a migraine attack. during the intravenous infusion of eptinezumab, some patients experiencing an ongoing migraine attack report its resolution. this finding is known in the literature, having been described in the relief study. this study was designed to also evaluate, in a real-world setting, the efficacy of eptinezumab in resolving the ongoing attack and the time frame within which the attack is resolved. the study includes all patients who will begin treatment according to clinical practice, and are included in the tachis study (nct06409845, unique protocol id rice_5)


Eligibility criteria:
inclusion criteria: * diagnosis of migraine without aura, migraine with aura, or chronic migraine according to the third edition of the ichd (ichd-iii). * at least 8 days of migraine per month. * adequate compliance with study procedures. * availability of a migraine diary for at least one month prior to enrollment. * ongoing attack before administration. * included in the tachis study (nct06409845) exclusion criteria: * subjects with contraindications to the use of eptinezumab. * concomitant diagnosis of medical conditions and/or comorbidities that, in the investigator's opinion, could interfere with the study's assessments and outcomes. * pregnancy and breastfeeding. * changes in concomitant preventive therapy in the month prior to the initiation of eptinezumab.

Keywords: headache pain migraine eptinezumab
risk factors of post-ercp pancreatitis in patients receiving rectal indomethacin

Conditions: Healthy

Summary: post-endoscopic retrograde cholangiopancreatography(ercp) pancreatitis (pep)remains the most frequent adverse event of ercp. rectal indomethacin, as one kind of classic nsaids, has been proved to be effective in reducing the incidence of pep. it has been widely used to prevent pep in patients, especially those with potentially high risks of pep. however, rectal indomethacin can not completely eradicate the occurrence of pep. the rate of pep in patients receiving indomethacin ranges from 3.2% to 9.2%. the risk factors of pep in patients receiving rectal indomethacin remains unclear. the aim of the study was to identify potential risk factors in high-risk patients whose received administration of prophylactic rectal indomethacin after ercp.


Eligibility criteria:
inclusion criteria: * undergoing diagnostic or interventional ercp * receiving administration of rectal indomethacin(100mg) after ercp * high risk patients determined at the discretions of endoscopists exclusion criteria: * dose other than 100mg * acute pancreatitis within 3 days before ercp * average risk patients at the discretions of endoscopists * using nsaids within 7 days before ercp * without cannulation attempts * administration of rectal indomethacin before or during ercp

Keywords: post-endoscopic retrograde cholangiopancreatography pancreatitis risk factors indomethacin
etablishment of follow-up system and end-stage heart registration platform for pediatric heart failure

Conditions: Heart Failure; Congenital; End-stage Heart Failure

Summary: establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure


Eligibility criteria:
inclusion criteria: * patients younger than 14 years of age * refractory heart failure exclusion criteria: -

Keywords: congenital heart failure registry end-stage heart failure
the importance of electrical stimulation as a treatment for urinary incontinence in patients prostatectomy

Conditions: Urinary Incontinence

Summary: the use of electrical stimulation to reduce urinary incontinence in men undergoing prostatectomy exercises of the pelvic floor muscles (maps)

the study will be an experiment with active control, randomized, double-blind, parallel intervention. after met the eligibility criteria of the patients will be randomly allocated into two groups: group exercises maps (gex), which is the active control group and electrostimulation + exercises maps (geex).

Eligibility criteria:
inclusion criteria: * patients with urinary sphincter deficiency resulting from a radical prostatectomy surgery * sent by urologists the same hospital where the experiment will take place * having the maximum time six months after surgery * to use 2 to 5 disposable protective per day exclusion criteria: * symptoms of urinary tract infection * symptoms of lower urinary tract obstruction * anal fistula * metallic implant in the body * transurethral resection of prostate * radiation therapy * non-enforcement of the proposed treatment.
opium tincture against chronic diarrhea - patients

Conditions: Chronic Diarrhea

Summary: the purpose of this study is to investigate the mechanistic anti-propulsive effects of opium tincture on the gastrointestinal tract of a cohort of patients with chronic diarrhea

opium tincture is used a symptomatic drug against chronic diarrhea even though no clinical studies have investigated the effect on gastrointestinal function. with this randomized, double-blind, placebo-controlled cross-over trial in 16 patients with chronic diarrhea, we wish to provide evidence-based insights into the effects of opium tincture on gastrointestinal function. additionally, effects on the central nervous system will be investigated a tertiary aim.

Eligibility criteria:
inclusion criteria: * • signed informed consent before any study specific procedures * able to read and understand danish * male or female with an age of 20 years or more * the researcher believes that the participant understands what the study entails, are capable of following instructions, can attend when needed, and are expected to complete the study. * the investigator will ensure that fertile female participants have a negative pregnancy test before each treatment visit and use contraception during the entity of the study. * specific underlying pathophysiology has been identified, but targeted treatment (e.g. antibiotics or bile acid sequestrants) and treatment with loperamide has failed. or * no specific underlying pathophysiology has been identified and treatment with loperamide has failed. * at least 6 months post-surgery in the gastrointestinal tract * no sign of cancer at standard clinical follow-up * chronic diarrhea defined as at least 3 daily bowel movements for the last week exclusion criteria: * • known allergy towards pharmaceutical compounds similar to dropizol. * participation in other studies within 14 days of first visit (1 year if opioids involved). * expected need of medical/surgical treatment during the study * history of psychiatric illness (e.g. mental retardation, schizophrenia, major depression) * history of substance abuse (e.g. alcohol, thc, benzodiazepine, central stimulants and/or opioids) * family history of substance abuse * known major stenosis of the intestines * known severe decreased renal function (defined as egfr below 30) * known severe decreased hepatic function (defined as child-pugh class b or higher) * treatment with mao- inhibitors during the entity of the study * severe copd or acute severe asthma (defined as fev1 below 50 % or acute ongoing exacerbation) * known cor pulmonale * female participants that are lactating * medicine known to affect gastrointestinal motility must not be initiated during the entity of the study * treatment with opium tincture during the last month

Keywords: diarrhea gastrointestinal transit
early screening of hepatocellular carcinoma in cirrhotic patients: a prospective study

Conditions: Cirrhosis; Hepatocellular Carcinoma

Summary: although serum alpha-fetoprotein level and abdominal sonography are the main methods to screening hepatocellular carcinoma (hcc) in cirrhotic patients, the adequate time and methods used are not completely well-defined. this study aims to assess the better timing and methods for prospectively screening hcc in patients with cirrhosis

well-diagnosed consecutive patients with cirrhosis were enrolled through a designed questionnaire to obtain basic information about gender, age, etiology of cirrhosis, conventional liver function tests, serum afp level, education level, substance use including smoking, alcohol drinking, betel quid chewing, history of familial hcc, etc. then the patients was followed by periodic abdominal sonography examination and determination of afp and liver function. if afp elevated or liver nodule appears, effort to diagnose hcc will be performed.if hcc was performed, the survival will be followed-up. as anti-viral therapy was found to decrease risk for hcc, patients with those therapy will be excluded.

Eligibility criteria:
inclusion criteria: * image diagnosis or biochemical diagnosis or presence of portal hypertension exclusion criteria: * presence of hepatocellular carcinoma
volume of perirenal fat and chronic kidney disease

Conditions: Nephrectomy

Summary: the perirenal fat may alter renal function by secreting fibrotic inflammatory agents when accumulates during obesity. nephrectomy for renal tumor is a model that would provide tissue samples to test this hypothesis. renal tumor could itself be responsible for inflammation and fibrosis in its environment. this study aims to measure the influence of the tumor on his kidney environment and fat and define molecular markers not influenced by renal tumor. the main objective is to compare the inflammation of the perirenal fat taken in two locations in the same patient, in contact and 4 cm from the outer edge of the tumor, each patient as his own control. the secondary objective is to compare the degree of interstitial fibrosis of the renal cortex in the same sampling methods.


Eligibility criteria:
inclusion criteria: * age 18 years or more * indication nephrectomy for kidney tumor * stadium t1a, t1b or t2 and m0 according to the tnm (tumor nodes metastasis) classification of tumors exclusion criteria: * nephrectomy indication for chronic pyelonephritis * asian topic because of the difference threshold values used to characterize the metabolic syndrome in this population * diabetes type i or ii due to a high score of renal interstitial fibrosis * infection with hiv (human immunodeficiency virus) * partial nephrectomy (a part of the kidney on the side of the tumor is left in place)
venous thromboembolism in primary pancreatic tumour resection

Conditions: Venous Thromboembolism; Pancreatic Cancer; Pancreatic Ductal Adenocarcinoma

Summary: this study will evaluate the development of venous thromboembolism (vte) and possible determinants in patients with primary pancreatic cancer undergoing pancreatic cancer resection.

cancer associated thrombosis (cat) is the second cause of death, in oncologic patients after tumour progression itself. patients suffering from malignancies are at increased risk for both venous (4-20%) and arterial (2-5%) thrombotic events. moreover, cancer is one of the most important acquired risk factors for the development of venous thromboembolism (vte). pancreatic cancer is the fourth most deadly cancer world-widely and has been recognised as the most prothrombotic malignancy, with a reported incidence of vte (8-18%), followed by renal and ovarian cancer (vte 5.6%). although the exact pathophysiological mechanisms are still poorly understood it seems that pancreatic cancer induces a prothrombotic and hypercoagulable state. aims * to evaluate the predictive value of preoperatively or early postoperatively obtained nlr, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for vte up to the 30rd postoperative day * to evaluate the predictive value of preoperatively or early postoperatively obtained coagulation biomarkers/parameters, in patients with primary pancreatic cancer undergoing pancreatic cancer resection, for vte up to the 30rd postoperative day * to evaluate the incidence of vte in patients with primary pancreatic cancer undergoing pancreatic cancer resection * to assess the perioperative coagulation status of patients with primary pancreatic cancer undergoing pancreatic cancer resection * to evaluate any possible determinant or predictive factor for vte among the coagulation parameters or patients' baseline characteristics

Eligibility criteria:
inclusion criteria: * consecutive pancreatic cancer patients undergoing pancreatic cancer resection in university hospital of larissa, after informed consent will be included. exclusion criteria: * refuse to participate * previous thromboembolic event \< 6 months prior to the operation * history of inherited or acquired bleeding disorder * asa ps \> 3 * concomitant presence of a second primary malignancy * unresectable pancreatic cancer
evaluation of impacted or included maxillary canines on dentofacial structures, and airway and nasal fossa dimensions

Conditions: Impacted Canines; Maxillary Sinus

Summary: the study retrospectively analyzed previously acquired cbct images to evaluate specific anatomical features, such as \[e.g., "maxillary sinus and nasal fossa volumes"\]. no active patient participation or new clinical procedures is required; this information is used to measure sinus and fossa dimensions.

the study analysed the cbcts of patients, each assigned to one of three groups: control, unilateral canine impaction, or bilateral canine impaction. each group was assigned by gender. three values were analysed: maxillary sinuses left (msl) and right (msr), and sinuses with fossa msnf measures in mm3.

Eligibility criteria:
inclusion criteria: * unilateral or bilateral canine inclusion, * young pacients between 10 and 23 years old. exclusion criteria: * pregnant women, * major craniofacial deformities (such as cleft palate, severe asymmetric malocclusion, trauma or head \& neck oncologic surgery), * surgeries other than maxillomandibular advancement, * patients with maxillary compression or syndromes * any nasal or nasopharyngeal airway obstruction. * skeletal, dental or dentoalveolar transversal or vertical issues
thromboelastography as an assessment tool for possible clopidogrel and aspirin resistance

Conditions: Acute ST SEgment Elevation Myocardial Infarction

Summary: teg is an established technique to assess the quality of clot formation' used mainly in surgery and obstetrics to determine possible bleeding diathesis. recently it became to be used in cardiology, where it can be a valuable tool to assess a response to antiplatelet therapy and its association with the outcome. however, there is a few data about use of teg in stemi patients undergoing pci. our study is designed to assess by teg the platelet's response to clopidogrel treatment during acute stemi in patients undergoing primary pci and the correlation of this response with the long term outcome, and ability to dose adjustment according to a specific measurement by teg in order to prevent future mace.

teg system may provide the capabilities needed to deliver personalized therapy, first, because it can identify patients at risk of ischemic event based on hemostatic influences, particularly platelet aggregation and platelet reactivity. secondly, because treating those patients who exhibit high platelet reactivity -- an indication that they are not reaching a therapeutic level -- with appropriate drugs and doses is expected to improve outcomes. in this study that would be increased clopidogrel maintenance dosing (150 mg) or aspirin maintenance dosing to 200mg in an attempt to lower platelet reactivity below the 50th%ile, which we expect to also reduce their ischemic risk during the follow up period.

Eligibility criteria:
inclusion criteria: * patients 18 years of age or more * patients admitted with acute stemi as a first coronary event * duration of symptoms less than 12 hours * pci elected as a treatment of acute stemi * informed consent signed exclusion criteria: * thrombolytic therapy * pci not performed after diagnostic angiography (conservative treatment, cabg) * des used in ppci * staged pci procedures * previous clopidogrel treatment at any time for any reason * previous myocardial infarction * known bleeding diathesis of any kind * significant renal insufficiency (gfr\<40 ml/min) * lft disturbances (transaminase elevation more than x3 uln) * significant anemia (hb\<10) or a need for blood transfusion * significant thrombocytopenia (plt count \< 150000) * known clopidogrel allergy * known active peptic disease

Keywords: thromboelastography aspirin clopidogrel plavix resistance platelet coronary stenting bare metal stent dual antiplatelet therapy overreactivity primary coronary intervention
outpatient based physical rehabilitation for survivors of prolonged critical illness

Conditions: Rehabilitation After Critical Illness

Summary: admission to an intensive care unit (icu) due to illness has been shown to have a dramatic effect on the human body and mind. following discharge from an icu, patients suffer from varying degrees of weakness and muscle wasting. it can take many months before their strength returns to something like before they were ill. this weakness can have important consequences on an individual, affecting their ability to perform routine tasks (e.g. housework, shopping), and whether they can return to work or not. not surprisingly, this inability to perform activities they used to do prior to their illness can have knock on effects on their mental well being and confidence. what the investigators hope to see through this study is whether or not patients can recover their ability to perform exercise more quickly following an icu admission if they undergo an exercise-based rehabilitation programme. the investigators also hope to see whether taking part in a rehabilitation programme has any affect on physical and mental well being. the investigators hope to use a simple exercise test on a bicycle to assess subjects ability to exercise shortly after leaving hospital. we will then repeat the test after a period of physiotherapy lead rehabilitation to see if they have received any benefit from the programme. the investigators hope to show that by undergoing an exercise-based rehabilitation programme subjects will recover their ability to exercise more quickly than those who do not. by means of questionnaires the investigators hope to see what effect the rehabilitation programme has had on participants physical and mental well being.


Eligibility criteria:
inclusion criteria: all patients over the age of 18 * admitted to a single, tertiary centre united kingdom general intensive care unit (icu) * invasively ventilated ≥ 5 days exclusion criteria: * physical condition resulting in an inability to perform a cardio-pulmonary exercise test (cpet) or to participate in the rehabilitation classes, * psychiatric condition or impairment not allowing informed consent or compliance with the rehabilitation programme, * participation in an alternative rehabilitation programme, * terminal illness * poorly controlled cardio-respiratory disease
safety and immunogenicity of two doses of h5n1 influenza vaccine in elderly subjects

Conditions: Pandemic H5N1 Influenza

Summary: evaluate safety, tolerability and immune response of adjuvanted h5n1 cell culture derived influenza vaccine in elderly subjects


Eligibility criteria:
inclusion criteria: 1. healthy elderly subjects ≥65 years, 2. individuals willing to provide written informed consent, 3. individuals in good health, 4. individuals willing to allow for their serum samples to be stored beyond the study period. exclusion criteria: 1. individuals not able to understand and follow study procedures, 2. history of any significant illness, 3. history of any serious chronic medical condition or progressive disease, 4. presence of medically significant cancer, 5. known or suspected impairment/alteration of immune function, 6. presence of any progressive or severe neurologic disorder, 7. presence of any bleeding disorders or conditions that prolongs bleeding time, 8. history of allergy to vaccine components, 9. receipt of any other investigational product within 30 days prior to entry into the study, 10. history of previous h5n1 vaccination, 11. receipt of any other type of seasonal vaccination within 2 months prior to entry into the study, 12. receipt of any other vaccine within 2 weeks prior to entry into the study 13. body temperature ≥38°c.0 (≥100.4° f) and/or acute illness within 3 days of intended study vaccination, 14. body mass index (bmi) ≥ 35 kg/m2, 15. history of drug or alcohol abuse, 16. any planned surgery during study period, 17. individuals conducting the study and their immediate family members, 18. individuals with behavioral or cognitive impairment or psychiatric diseases.

Keywords: influenza, pandemic, h5n1, elderly adults